P2, N=70, Active, not recruiting, Inspirna, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Aug 2028 --> Dec 2026 | Trial primary completion date: Aug 2026 --> Sep 2025

P1, N=108, Recruiting, Inspirna, Inc. | N=60 --> 108 | Trial primary completion date: Dec 2023 --> Dec 2024

P2, N=70, Recruiting, Inspirna, Inc. | N=50 --> 70

P2, N=50, Recruiting, Inspirna, Inc.

P2, N=50, Recruiting, Inspirna, Inc. | Not yet recruiting --> Recruiting

P2, N=50, Not yet recruiting, Inspirna, Inc.

Eligible pts had disease progression after a 1L oxaliplatin-containing regimen...There is a high unmet need for a safe and combinable oral pan-RASm therapy in mCRC. Recruitment of RASm pts continues and a randomized controlled trial in 2L RASm mCRC is planned.

P1, N=60, Recruiting, Inspirna, Inc. | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: May 2023 --> Dec 2023

P1, N=60, Recruiting, Inspirna, Inc. | Trial completion date: May 2022 --> Dec 2023 | Trial primary completion date: Dec 2021 --> May 2023

Decreased creatine levels can reduce ATP production and impair CD8+ T cell immune function, leading to immune escape by leukemic cells. In summary, leukemic cell-derived sEV-related miR-19a-3p confers immunosuppression to CD8+ T cells by targeting SLC6A8-mediated creatine import, indicating that sEV-related miR-19a-3p might be a promising therapeutic target for NPM1-mutated AML.

Our study indicates that SLC6A8-mediated creatine accumulation plays an important role in promoting TNBC progression, and may provide a potential therapeutic strategy option for treatment of SLC6A8 high expressed TNBC.

GATM knockdown or MPS1 inhibition suppresses cancer metastasis and benefits mouse survival by downregulating Snail and Slug. Our findings call for using caution when considering dietary creatine to improve muscle mass or treat diseases and suggest that targeting GATM or MPS1 prevents cancer metastasis, especially metastasis of transforming growth factor beta receptor mutant colorectal cancers.

SLC6A8 promotes the malignant progression of NSCLC and activates the Notch signaling pathway. Therefore, SLC6A8 is expected to become a molecular target for NSCLC treatment.

These results enhance our understanding of the composition and prognostic significance of tumor-infiltrating immune cells in NPC lesions, and provide potential targets for prognostication and immunotherapy for NPC patients.

These studies identify kinase regulation of the Na/K-ATPase as pivotal in regulating creatine uptake and energy metabolism in cells.

Among 17 patients treated with single agent therapy, no DLTs occurred; notably, exposures predicted to be sufficient to inhibit human tumor growth from preclinical models were achieved along with concomitant pharmacodynamic effects. These data, along with a durable PR observed in the highest dose cohort, support further development of RGX-202. Consequently, dose escalation in combination with FOLFIRI in patients with advanced GI cancers is underway with plans for expansion in CKB+ CRC pts.